Quick Answer
Organogenesis Holdings Inc. reported Stockholders Equity of $300.13 million for the year ending 2025.
- Organogenesis Holdings Inc. showed an increase of +14.2% in Stockholders Equity from 2024 to 2025.
- This data is from Organogenesis Holdings Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: -$30.7 thousand | Q1 2017: $5.00 million | Q2 2017: $5.00 million | Q3 2017: $5.00 million | Q1 2018: -$37.44 million | Q2 2018: -$57.17 million | Q3 2018: -$24.23 million | Q1 2019: $32.56 million | Q2 2019: $23.20 million | Q3 2019: $12.81 million | Q1 2020: $40.30 million | Q2 2020: $31.83 million | Q3 2020: $61.38 million | Q1 2021: $153.02 million | Q2 2021: $174.65 million | Q3 2021: $189.17 million | Q1 2022: $241.53 million | Q2 2022: $254.39 million | Q3 2022: $256.33 million | Q1 2023: $263.70 million | Q2 2023: $271.28 million | Q3 2023: $276.87 million | Q1 2024: $278.03 million | Q2 2024: $263.50 million | Q3 2024: $278.55 million | Q1 2025: $242.90 million | Q2 2025: $233.24 million | Q3 2025: $255.13 million.
- Historical annual values: Fiscal year 2025: $300.13 million | Fiscal year 2024: $262.90 million | Fiscal year 2023: $278.66 million | Fiscal year 2022: $265.67 million | Fiscal year 2022: $241.53 million | Fiscal year 2021: $241.34 million | Fiscal year 2020: $141.81 million | Fiscal year 2019: $52.02 million | Fiscal year 2018: $39.94 million | Fiscal year 2017: -$15.32 million | Fiscal year 2016: -$15.98 million | Fiscal year 2015: $3.51 million | Fiscal year 2015: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: